Theratechnologies (TSE:TH) Hits New 52-Week High - Should You Buy?

Key Points

• Theratechnologies Inc. shares reached a new 52-week high of C$4.54 during trading, though the stock was last traded at C$4.54 after a previous close of C$4.59.
• Analysts have mixed opinions on the stock, with Jones Trading downgrading it from a "strong-buy" to a "hold," while the consensus rating remains a "Buy."
• The company specializes in pharmaceutical products for HIV patients and has a market cap of C$207.83 million, with a notable debt-to-equity ratio of -293.92.

Theratechnologies Inc. (TSE:TH - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as C$4.54 and last traded at C$4.54, with a volume of 3537 shares. The stock had previously closed at C$4.59.

Wall Street Analysts Forecast Growth

Separately, Jones Trading cut shares of Theratechnologies from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 3rd. One research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy".

Theratechnologies Price Performance

The company has a debt-to-equity ratio of -293.92, a quick ratio of 0.64 and a current ratio of 1.08. The business has a 50 day simple moving average of C$4.40 and a 200-day simple moving average of C$3.53. The stock has a market cap of C$207.83 million, a P/E ratio of -23.79, a P/E/G ratio of -8.50 and a beta of 0.26.

About Theratechnologies

Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.